GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Shares Outstanding (EOP)

TARS (Tarsus Pharmaceuticals) Shares Outstanding (EOP) : 38.2 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Tarsus Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2024 was 38.2 Mil.

Tarsus Pharmaceuticals's quarterly shares outstanding increased from Jun. 2024 (38.0 Mil) to Sep. 2024 (38.2 Mil). It means Tarsus Pharmaceuticals issued new shares from Jun. 2024 to Sep. 2024 .

Tarsus Pharmaceuticals's annual shares outstanding increased from Dec. 2022 (26.7 Mil) to Dec. 2023 (34.2 Mil). It means Tarsus Pharmaceuticals issued new shares from Dec. 2022 to Dec. 2023 .


Tarsus Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Tarsus Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Shares Outstanding (EOP) Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 2.36 20.32 20.70 26.73 34.21

Tarsus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.10 34.21 37.75 38.03 38.20

Competitive Comparison of Tarsus Pharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsus Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Shares Outstanding (EOP) falls into.



Tarsus Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Tarsus Pharmaceuticals  (NAS:TARS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Tarsus Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tarsus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Executives
Link William J Phd director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jeffrey S Farrow officer: See Remarks TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Dianne C. Whitfield officer: Chief Human Resources Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl officer: General Counsel 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Seshadri Neervannan officer: Chief Operating Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bobak R. Azamian director, 10 percent owner, officer: President and CEO 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jose M. Trevejo officer: Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Leonard M. Greenstein officer: Chief Financial Officer 24562 BELGREEN PLACE, LAKE FOREST CA 92630
Mark J. Holdbrook officer: V.P., Clinical Affairs 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann director, 10 percent owner 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540